Vanda Pharmaceuticals
VNDA
168 hedge funds and large institutions have $704M invested in Vanda Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 78 increasing their positions, 44 reducing their positions, and 22 closing their positions.
77% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 44
18% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 22
2% more funds holding
Funds holding: 164 → 168 (+4)
3.06% less ownership
Funds ownership: 102.51% → 99.45% (-3.1%)
7% less capital invested
Capital invested by funds: $759M → $704M (-$55.4M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
70% less call options, than puts
Call options by funds: $378K | Put options by funds: $1.27M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.73M |
| 2 |
Prudential Financial
Newark,
New Jersey
|
+$8.39M |
| 3 |
Renaissance Technologies
New York
|
+$5.72M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$5.66M |
| 5 |
AC
Armistice Capital
New York
|
+$5.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$51.1M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$18.9M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$6.6M |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$5.93M |
VNDA Hedge Fund Activity: Q3 2019 in Review
168 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2019, worth a combined $704M — down 7.3% from $759M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new VNDA positions and 22 closed out — a net gain of 4 holders — while 78 added to existing stakes and 44 trimmed.
The largest buyer was Vanguard Group, adding an estimated $9.73M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $51.1M sold.
- 168 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2019, up from 164 in Q2 2019.
- Funds reported $704M of Vanda Pharmaceuticals stock for Q3 2019, down 7.3% quarter-over-quarter.
- 26 funds opened new Vanda Pharmaceuticals positions in Q3 2019 and 22 closed out, a net change of +4 holders.
- The largest Vanda Pharmaceuticals buyer in Q3 2019 was Vanguard Group, an estimated $9.73M added.
- The largest Vanda Pharmaceuticals seller in Q3 2019 was Consonance Capital Management, an estimated $51.1M sold.
Based on aggregated 13F filings for Q3 2019.